All In Biotech

Drug Trial Radar · NCT06584071

A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC

A Phase Ib/II Clinical Trial to Evaluate the Preliminary Efficacy, Safety and Pharmacokinetics of PM8002 Injection Combined With PM1009 Injection in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: Dec 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Dec 2024

Primary completion

Oct 2026

Study completion Dec 2027

Sponsor

Lead sponsor
Biotheus Inc.Industry
Sponsor type
Industry
First posted
Sep 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study to evaluate the preliminary efficacy, safety and pharmacokinetics of PM8002 combined with PM1009 in Patients with first-line Hepatocellular Carcinoma.

Conditions

  • HCC
  • Liver Cancer

Interventions

  • PM8002Drug

    PM8002 via IV infusion, Q3W

  • PM1009Drug

    PM8002 via IV infusion, Q3W

  • atezolizumabDrug

    atezolizumab,1200mg, via IV infusion, Q3W

  • bevacizumabDrug

    bevacizumab,15mg/kg, via IV infusion, Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate(ORR)Time frame: Up to approximately 2 years
  2. Optimal dosing regimen of PM8002 in combination with PM1009Time frame: Up to approximately 2 years
  3. Treatment related adverse events (TRAEs)Time frame: Up to 30 days after last treatment

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.